Skip to main content

JHOP - April 2020 Vol 10, No 2

Original Article

From the Literature

Symptom Management Overview

GU Cancers Symposium Highlights

GI Cancers Symposium Highlights

Rapid Onset of Severe Transaminitis in a Patient with Non–Small-Cell Lung Cancer After First Dose of Nivolumab 480 mg

Matthew Stankowicz, PharmD, BS; Megan Banaszynski, PharmD, BCOP; Russell Crawford, RPh, BCOP

Original Article

Clinical Outcomes Using Carboplatin Desensitizations in Patients with Gynecologic Cancer

Eris Tollkuci, PharmD, BCOP; Anna Chalmers, MD; Kathryn Schultz, PharmD, BCPS, BCOP; Sanjib Basu, PhD; Summer Dewdney, MD; Lydia Usha, MD

Extended versus Intermittent Infusions of Piperacillin-Tazobactam in Patients with Febrile Neutropenia

Daniel J. Przybylski, PharmD; David J. Reeves, PharmD, BCOP

Reduction in Utilization and Costs Associated with Formulary Restrictions of Injectable Calcitonin

Robert Walchack, PharmD, BCOP; Jordan Hill, PharmD, BCOP; Sijin Wen, PhD; Aaron Cumpston, PharmD, BCOP

From the Literature

Adding Tucatinib to Trastuzumab and Capecitabine Improves Survival in HER2-Positive Metastatic Breast Cancer

Trastuzumab Deruxtecan Shows Durable Antitumor Activity in HER2-Positive Metastatic Breast Cancer

Commentary by Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

First-Line Osimertinib Therapy Boosts Overall Survival in Non–Small-Cell Lung Cancer

Symptom Management Overview

Prevention of Chemotherapy-Induced Nausea and Vomiting in Adult Patients Undergoing Hematopoietic Stem-Cell Transplant: Is Olanzapine an Option?

By Ariel Denson, PharmD; Alyshia Wiggins, PharmD; Allison Martin, PharmD, BCOP; Justin Arnall, PharmD, BCOP, CPP

AVBCC Webcast Highlights: COVID-19 Impact on the Cancer Care Delivery Ecosystem

GU Cancers Symposium Highlights

Meeting Highlights

Sitravatinib, Novel TKI, plus Nivolumab Elicits Good Responses in Renal-Cell Carcinoma

Meeting Highlights

First-in-Class Oral MK-6482 Shows Exciting Results in Clear-Cell Renal-Cell Carcinoma

GI Cancers Symposium Highlights

Meeting Highlights

Gemcitabine-Cisplatin Combination a New Standard in Pancreatic Cancer with Germline BRCA or PALB2 Mutation

Meeting Highlights

Encorafenib plus Cetuximab Improves Quality of Life versus Standard of Care in Colorectal Cancer Associated with BRAF Mutation

Meeting Highlights

Atezolizumab-Bevacizumab Combo Improves Survival and Quality of Life in Unresectable Liver Cancer